{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:59:13Z","timestamp":1787162353856,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Swiss ALS Foundation","award":["2-70664-14"],"award-info":[{"award-number":["2-70664-14"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejmech.2017.12.097","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T03:00:53Z","timestamp":1515121253000},"page":"746-759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6\/2 chorea huntington mouse model and human ALS spinal cord tissue"],"prefix":"10.1016","volume":"145","author":[{"given":"Achi","family":"Haider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne M\u00fcller","family":"Herde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshuai","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Margelisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Schibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjing","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon M.","family":"Ametamey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.12.097_bib1","first-page":"34","article-title":"Marijuana in medicine: past, present and future","volume":"110","author":"Mikuriya","year":"1969","journal-title":"Calif. Med."},{"key":"10.1016\/j.ejmech.2017.12.097_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.12.097_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.12.097_bib4","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","article-title":"Cannabinoid pharmacology: the first 66 years","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0026-895X(25)10492-6","article-title":"Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors","volume":"48","author":"Felder","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International union of pharmacology. Xxvii. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2017.12.097_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/0091-3057(95)02066-7","article-title":"Aversive effects of the synthetic cannabinoid CP 55,940 in rats","volume":"53","author":"McGregor","year":"1996","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2017.12.097_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0006-8993(00)01981-8","article-title":"Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, \u03949-THC and anandamide1Published on the World Wide Web on 18 January 2000.1","volume":"857","author":"Houser","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2017.12.097_bib9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0022-3565(25)13256-4","article-title":"Pharmacology and stereoselectivity of structurally novel cannabinoids in mice","volume":"247","author":"Little","year":"1988","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2017.12.097_bib10","first-page":"133","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression, Best practice & research","volume":"23","author":"Moreira","year":"2009","journal-title":"Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1054\/plef.2001.0341","article-title":"Cannabinoid receptors and their ligands","volume":"66","author":"Pertwee","year":"2002","journal-title":"Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)"},{"key":"10.1016\/j.ejmech.2017.12.097_bib12","article-title":"Emerging role of the CB(2) cannabinoid receptor in immune regulation and therapeutic prospects","volume":"11","author":"Cabral","year":"2009","journal-title":"Expet Rev. Mol. Med."},{"issue":"24","key":"10.1016\/j.ejmech.2017.12.097_bib13","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1021\/acs.jmedchem.7b00155","article-title":"Perspectives of cannabinoid type 2 receptor (CB2R) ligands in neurodegenerative disorders: structure-affinity relationship (SAfiR) and structure-activity relationship (SAR) studies","volume":"60","author":"Spinelli","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.097_bib14","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejmech.2017.12.097_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bjp.0707493","article-title":"Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor","volume":"153","author":"Dittel","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib17","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2174\/138161208785740081","article-title":"The endocannabinoid system in amyotrophic lateral sclerosis","volume":"14","author":"Bilsland","year":"2008","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2017.12.097_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/157488912798842278","article-title":"Cannabinoids: novel medicines for the treatment of Huntington's disease","volume":"7","author":"Sagredo","year":"2012","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.ejmech.2017.12.097_bib19","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J.\u00a0Neurosci.: The Official J. Soc. Neurosci."},{"key":"10.1016\/j.ejmech.2017.12.097_bib20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrc882","article-title":"Molecular imaging of cancer with positron emission tomography","volume":"2","author":"Gambhir","year":"2002","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2017.12.097_bib21","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1021\/acs.jmedchem.6b00554","article-title":"Development of a high-affinity PET radioligand for imaging cannabinoid subtype 2 receptor","volume":"59","author":"Moldovan","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.097_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ejmech.2015.01.028","article-title":"Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor","volume":"92","author":"Slavik","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.097_bib23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.nucmedbio.2008.07.004","article-title":"Labelling and biological evaluation of [(11)C]methoxy-Sch225336: a radioligand for the cannabinoid-type 2 receptor","volume":"35","author":"Evens","year":"2008","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fnins.2016.00350","article-title":"Synthesis and biological evaluation of thiophene-based cannabinoid receptor type 2 radiotracers for PET imaging","volume":"10","author":"Haider","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2017.12.097_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/jnc.12354","article-title":"Radiolabeling and in\u00a0vitro\/in\u00a0vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor","volume":"126","author":"Mu","year":"2013","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2017.12.097_bib26","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/jnc.13716","article-title":"Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2","volume":"138","author":"Slavik","year":"2016","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2017.12.097_bib27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00259-014-2883-7","article-title":"Preclinical evaluation and test\u2013retest studies of [18F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5)","volume":"42","author":"Sephton","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2017.12.097_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2017.12.097_bib29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2017.12.097_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/B978-0-444-63425-2.00010-6","article-title":"The role of dopamine in Huntington's disease","volume":"211","author":"Cepeda","year":"2014","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejmech.2017.12.097_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0969-8051(94)00117-3","article-title":"Fluorinated benzamide neuroleptics\u2014III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenz-amide as an improved dopamine D-2 receptor tracer","volume":"22","author":"Mukherjee","year":"1995","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib32","first-page":"464","article-title":"Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET","volume":"45","author":"Honer","year":"2004","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2017.12.097_bib33","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.neuroimage.2012.05.075","article-title":"Quantification of dopamine D2\/3 receptors in rat brain using factor analysis corrected [18F]Fallypride images","volume":"62","author":"Millet","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.ejmech.2017.12.097_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneumeth.2010.12.027","article-title":"Assessment of IP injection of [18F]fallypride for behavioral neuroimaging in rats","volume":"196","author":"Yoder","year":"2011","journal-title":"J.\u00a0Neurosci. Meth."},{"key":"10.1016\/j.ejmech.2017.12.097_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0969-8051(94)00117-3","article-title":"Fluorinated benzamide neuroleptics\u2013III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer","volume":"22","author":"Mukherjee","year":"1995","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.neuropharm.2004.12.008","article-title":"Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy","volume":"48","author":"Valenzano","year":"2005","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/157015907780866884","article-title":"The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration","volume":"5","author":"Ashton","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00259-014-2883-7","article-title":"Preclinical evaluation and test-retest studies of [(18)F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5)","volume":"42","author":"Sephton","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2017.12.097_bib39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/ph7030339","article-title":"Synthesis and Preliminary Evaluation of a 2-oxoquinoline carboxylic acid derivative for PET imaging the cannabinoid type 2 receptor","volume":"7","author":"Mu","year":"2014","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2017.12.097_bib40","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijcard.2014.04.071","article-title":"Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules","volume":"174","author":"Muller","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejmech.2017.12.097_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417311285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417311285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T07:03:29Z","timestamp":1751180609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417311285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":42,"alternative-id":["S0223523417311285"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.097","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6\/2 chorea huntington mouse model and human ALS spinal cord tissue","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}